Friday, 16 October 2026European Markets

ACANTHE DEV. Stock Was Up By 17.38% On Monday

Loading stream...

(vianews) - the market ended the session with acanthe dev. (acan.pa) jumping 17.38% to €0.36 on monday, following the last session's downward trend. cac 40 fell 0.21% to €7,449.44, after two consecutive sessions in a row of gains, on what was a somewhat negative trend trading session today.

acanthe dev.'s last close was €0.31, 38.76% below its 52-week high of €0.50.

about acanthe dev.

as of december 31, 2022, acanthe développement's real estate portfolio represents an area of 9,374 m². during the year, the group sold, for €9.2 million, lots held in a building located on the left bank in paris. all of the group's buildings have been subject to appraisals, mainly carried out by the firm vif expertise on december 31, 2022. the overall appraised value of the property portfolio (investment properties and building occupied by the group) amounts to €117.1 million, an increase, at constant scope, of €1.6 million (+1.4%) compared to 2021. this increase in value confirms the relevant investment policy of the group in the central business district of paris. the appraised value of the assets stands at €117.1 million.

earnings per share

as for profitability, acanthe dev. has a trailing twelve months eps of €-0.08.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -8.6%.

revenue growth

year-on-year quarterly revenue growth grew by 7.7%, now sitting on 3.97m for the twelve trailing months.

more news about acanthe dev. (acan.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com